INS CD-PRESCRIP DRUG ACCESS
HB3752 would create a new statewide prescription drug continuity-of-care requirement for health coverage in Illinois. Beginning January 1, 2027, group and individual accident and health insurance policies and managed care plans could not limit or exclude coverage for a prescription drug that an enrollee has been continuously using for at least six months, as long as the drug was originally selected by the enrollee’s prescribing provider while the enrollee was covered under the current or a previous health plan. The bill is aimed at preventing disruptions in treatment when a person changes plans or when a plan changes its formulary.
The bill also amends several other laws to make the same coverage requirement apply across major public and private coverage arrangements, including the State Employees Group Insurance Act, county and municipal self-insured plans, school employee coverage, HMOs, limited health service organizations, voluntary health services plans, and Medicaid. In effect, it adds Section 356z.80 to the Illinois Insurance Code and cross-references that new mandate throughout the insurance and public aid statutes so the rule applies broadly across the state’s health coverage system.
HB3752 would expand Illinois insurance mandates by requiring most health plans and public employee health programs to cover certain long-used prescription drugs without interruption. It would affect insurers, managed care plans, self-insured local government and school plans, state employee coverage, and Medicaid by limiting their ability to remove or deny coverage for a medication after an enrollee has been stable on it for six months or more. The bill would also require the Department of Insurance and, for some public plans, the Department of Central Management Services to enforce the new coverage standard.
No committee transcripts or recorded votes were provided, so there is no documented debate or roll-call history to gauge legislative sentiment. Based on the bill’s structure and caption, the measure appears consumer- and patient-protective, with an emphasis on continuity of care and avoiding forced medication changes. The absence of recorded opposition in the available materials means the overall sentiment cannot be measured directly from hearings or votes.
The main policy tension is between patient continuity and insurer or plan flexibility. Supporters would likely favor the bill because it protects enrollees from formulary changes and medication disruptions, especially for people who are stable on a prescribed drug. Potential opponents are insurers, managed care organizations, and public plan administrators, who may object to reduced formulary management, higher costs, or limits on utilization controls. Another possible point of contention is the breadth of the mandate, since the bill applies across private insurance, public employee plans, local government plans, school plans, HMOs, and Medicaid, making it a broad statewide coverage requirement rather than a narrow consumer protection.